Last reviewed · How we verify
Multi-Phenolic (PIPERINE)
At a glance
| Generic name | PIPERINE |
|---|---|
| Sponsor | Energique, Inc. |
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- rash
- fatigue
- lack of concentration
Common side effects
Key clinical trials
- Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms (PHASE2)
- Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI (NA)
- Curcumin-Piperine Supplementation in STEMI - SPICE STEMI Trial (NA)
- Methylglyoxal (MGO) Lowering Cocktail to Reduce Appetite in Obese Individuals (PHASE1,PHASE2)
- Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity (EARLY_PHASE1)
- Curcumin Supplementation in Cervical Cancer (NA)
- Study of High-Dose Resveratrol in Patients With Stable Ischemic Heart Disease (NA)
- Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multi-Phenolic CI brief — competitive landscape report
- Multi-Phenolic updates RSS · CI watch RSS
- Energique, Inc. portfolio CI